Do you want to publish a course? Click here

Evaluation of Plasma Magnesium Levels and its Correlation with Glycemic Control in Type 2 Diabetes Mellitus Patients

العلاقة بين مستويات المغنزيوم البلازمية و ضبط سكر الدم عند مرضى الداء السكري من النمط الثاني

1160   1   21   0 ( 0 )
 Publication date 2017
and research's language is العربية
 Created by Shamra Editor




Ask ChatGPT about the research

Type 2 Diabetes mellitus T2DM has been suggested to be the most common metabolic disorder associated with magnesium deficiency which has many adverse outcomes. The aim of this study was to evaluate plasma Mg in 126 T2DM patients recruited from Diabetes Centre in Lattakia, compare them to 70 healthy individuals, and assess the correlation between plasma Mg and HbA1c as a glycemic control biomarker. Magnesium was measured using xylidyl blue colorimetric method. HbA1c was measured using ion-exchange resin separation. The SPSS 19.0 software was used for statistical analysis. Mean plasma Mg concentrations of the diabetics was significantly lower than controls (P=0.0001). Plasma magnesium was negatively correlated with HbA1c (r=-0.5, P=0.0002). Plasma magnesium was below the normal reference range (1.9-2.5 mg/dL) in 47.6% of diabetics and 28.6% of controls. In conclusion, it is important to monitor Mg levels in both T2DM patients and non-diabetics and take procedures to correct hypomagnesaemia states.


Artificial intelligence review:
Research summary
تناولت الدراسة العلاقة بين مستويات المغنزيوم البلازمية وضبط سكر الدم عند مرضى الداء السكري من النمط الثاني (T2DM). شملت الدراسة 126 مريضاً من المراجعين لمركز السكري في مدينة اللاذقية، وقورنت نتائجهم بمجموعة من الأصحاء شملت 70 فرداً. تم قياس مستويات المغنزيوم باستخدام الطريقة اللونية Xylidyl Blue، وقياس HbA1c باستخدام الاستشراب المبادل للشوارد. أظهرت النتائج انخفاضاً ملحوظاً في تراكيز المغنزيوم البلازمية عند المرضى مقارنة بالأصحاء، وارتبطت المستويات المنخفضة للمغنزيوم بضبط سيء لمستويات السكر في الدم، مما يبرز أهمية مراقبة تراكيز المغنزيوم عند مرضى السكري النمط الثاني والأصحاء على حد سواء، واللجوء إلى المعاوضة الدوائية أو الغذائية عند حدوث العوز.
Critical review
دراسة نقدية: تعتبر هذه الدراسة خطوة هامة في فهم العلاقة بين مستويات المغنزيوم وضبط سكر الدم عند مرضى السكري من النمط الثاني. ومع ذلك، هناك بعض النقاط التي يمكن تحسينها. أولاً، كان من الممكن أن تكون العينة أكبر وأكثر تنوعاً لتشمل مناطق جغرافية مختلفة، مما قد يعزز من دقة النتائج. ثانياً، لم تتناول الدراسة بشكل كافٍ العوامل الغذائية والبيئية التي قد تؤثر على مستويات المغنزيوم، مثل نوعية الغذاء والنشاط البدني. ثالثاً، لم يتم التطرق إلى تأثير الأدوية الأخرى التي قد يتناولها المرضى على مستويات المغنزيوم. على الرغم من هذه النقاط، فإن الدراسة تقدم معلومات قيمة تستحق المتابعة في أبحاث مستقبلية.
Questions related to the research
  1. ما هو الهدف الرئيسي من الدراسة؟

    الهدف الرئيسي من الدراسة هو تقييم مستويات المغنزيوم البلازمية عند مرضى السكري من النمط الثاني ودراسة علاقتها بضبط سكر الدم ممثلاً بقيم HbA1c.

  2. ما هي الطريقة المستخدمة لقياس مستويات المغنزيوم في الدراسة؟

    تم قياس مستويات المغنزيوم باستخدام الطريقة اللونية Xylidyl Blue.

  3. ما هي النتائج الرئيسية التي توصلت إليها الدراسة؟

    أظهرت الدراسة انخفاضاً ملحوظاً في تراكيز المغنزيوم البلازمية عند مرضى السكري من النمط الثاني مقارنة بالأصحاء، وارتبطت المستويات المنخفضة للمغنزيوم بضبط سيء لمستويات السكر في الدم.

  4. ما هي التوصيات التي قدمتها الدراسة بناءً على النتائج؟

    أوصت الدراسة بضرورة مراقبة تراكيز المغنزيوم بشكل دوري عند مرضى السكري النمط الثاني والأصحاء، واللجوء إلى المعاوضة الدوائية أو الغذائية عند حدوث العوز.


References used
FEINGLOS, M.N.; BETHEL, M.A. Type 2 Diabetes Mellitus: An Evidence- Based Approach to Practical Management. contemporary Endocrinology. 2008, Humana Press, 2008, XIII, 474
PEREIRA, M.A. Nutrition and Type 2 Diabetes: Etiology and Prevention. CRC Press, 2013, 105-150
SWAMINATHAN, R. Magnesium metabolism and its disorders. Clin Biochem Rev, 24 (2), 2003, 47-66
rate research

Read More

Blood glucose control reduces the microvascular and macrovascular complications in patients with diabetes mellitus type II. According to the American Diabetes Association, less than a half of those with diabetes achieve optimal control of blood gluc ose and target values of HbA1c. Life style modifications is one of the preferences of diabetes management because the potential relationship between diet and diabetic control. So nutrition therapy which given by dietitian and generally lifestyle modifications are considered mainly integrated to traditional medication for disease. The study included 104 patients with diabetes type II (HbA1c 8% ± 1.07, BMI 26.45 ± 2.69, fasting blood glucose 148.25 ± 33.76) given diabetes self-management education program and divided into two groups. The first group was treated with glibenclamide only and the second was treated with a combination of glibenclamide and metformin. After three months monitoring, 103 patients Completed the study. Therapeutic efficacy was evaluated considering HbA1c ≤ 6.5% as a target value. The necessary statistical study to analyze the data and evaluate the statistical significance of the results was made. The results indicate that the treatment supported with life style modifications was more effective than traditional therapy and patient education at blood glucose control in patients with diabetes mellitus type II and improve their health.
Background: Diabetes mellitus type2 (T2DM) and thyroid dysfunction (TD) are the two most common endocrine disorders in clinical practice. The unrecognized TD may adversely affect the metabolic control and add more risk to an already predisposing s cenario for cardiovascular diseases. The objective of this study was to investigate the prevalence of TD in patients with type2 diabetes mellitus. Objective: To determine the prevalence and patterns of thyroid dysfunction in patients with type2 diabetes mellitus. Material and methods: Study included total 362 subjects (204 type2 diabetic patients and 158 healthy non diabetic subjects). Agroup of type2 diabetic patients and control group were evaluated for thyroid dysfunction by testing TSH and FT4 when TSH was abnormal. The correlation of prevalence of thyroid disorder with gender distribution, age distribution, duration of diabetes, BMI, treatment, fasting plasma glucose (FPG), serum triglyceride and serum cholesterol was then done in diabetic patients. The observations and interpretations were recorded and results obtained were statistically analyzed. Results: The prevalence of thyroid dysfunction among type2 diabetic patients was found to be 13,2%. In the control group, the prevalence of thyroid dysfunction was 6,3%. There was a significant difference between diabetics and control subjects p= 0,031.The most frequently TD in type2 diabetic patients was subclinical hypothyroidism (8,3%). Thyroid dysfunction was significantly correlated with gender (women > man), age < 60 years, FPG > 130mg/dl, TG > 150mg/dl and insulin treatment in type2 diabetic patients. Conclusion: Screening of thyroid dysfunction shoud be done in all Type2 diabetic patients.
This study aims to compare between two globally approved strategies to manage diabetes type II in Syria, by comparing their effectiveness in patients with diabetes type II who are treated in the national program of diabetes Clinics in Damascus and in vestigate their glucose control. The first strategy includes glibenclamide as a monotherapy and the second includes a combination of glibenclamide and metformin.
Many T2D use CAO as a laxative. We did not find sufficient research to explain CAO's potential effect on the levels of HbA1c in T2D patients. This study will study this effect. Rats (n=80) were divided into eight groups (n=10). Five groups (n=50) wer e injected with streptozotocin intravenously to induce T2D. One group was given CAO with empagliflozin, and the second was assigned CAO only daily. The third was assigned CAO every two days, with empagliflozin, which was given daily. A fourth was assigned CAO alone daily. Also, the fifth was given empagliflozin alone. In the healthy groups, one group was given CAO, and the other was given empagliflozin. Also, the last healthy group was not assigned any drug. CAO's result on HbA1c in healthy rats was noted to decrease when delivered alone for eight weeks. HbA1c of the diabetic groups showed no significant difference (P-value<0.05) when comparing the rats given CAO with empagliflozin, and the rats were given CAO only. There was also no noticeable effect among the groups of rats given CAO daily and every two days. This study explains that CAO does not lead to a significant difference in HbA1c levels in diabetic rats, even it did for healthy rats, and if given alone, CAO could affect HbA1c levels if given over a long period. Also, CAO has a noticeable impact on experimental rats that co-administered Empagliflozin on HbA1c levels, and that Empagliflozin effect is not significantly affected if taken with CAO.

suggested questions

comments
Fetching comments Fetching comments
Sign in to be able to follow your search criteria
mircosoft-partner

هل ترغب بارسال اشعارات عن اخر التحديثات في شمرا-اكاديميا